BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved January 23, 2026 for 12 new employees totaling 34,199 restricted stock units. Awards were granted under the company's Amended and Restated 2019 Inducement Equity Plan.

Vesting: one‑quarter of each employee's RSUs vest on November 16, 2026, then one‑twelfth of the remaining shares vest quarterly thereafter, subject to continued employment. The Plan was originally adopted in November 2019 and amended and restated on February 10, 2023 and December 13, 2023. Grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).

Key Figures

Inducement RSUs granted: 34,199 shares New employees: 12 employees Initial vesting: One-fourth of RSUs +1 more

4 metrics

Inducement RSUs granted 34,199 shares Aggregate restricted stock units to 12 new employees

New employees 12 employees Recipients of inducement restricted stock unit grants

Initial vesting One-fourth of RSUs Vesting on November 16, 2026, subject to continued employment

Ongoing vesting schedule One-twelfth quarterly Remaining RSUs vest quarterly after initial tranche

Market Reality Check

Price: $77.87 Vol: Today’s volume of 3,866,4...

normal vol

$77.87 Last Close

Volume Today’s volume of 3,866,485 shares is 1.32x the 20-day average. normal

Technical Shares at $77.81, trading above the 200-day MA of $53.06 and 4.32% below the 52-week high.

Peers on Argus

BBIO slipped 0.08% while biotech peers were mixed: BMRN +1.72%, IONS +1.90%, SMM...

BBIO slipped 0.08% while biotech peers were mixed: BMRN +1.72%, IONS +1.90%, SMMT +1.66%, EXEL -1.93%, ASND -0.40%, indicating stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 16	Convertible notes pricing	Positive	+0.0%	Priced $550M 2033 convertible notes and concurrent share repurchase program.
Jan 14	Debt offering launch	Neutral	-2.1%	Announced proposed $550M 2033 convertible notes to manage 2027 maturities.
Jan 12	JPM business update	Positive	-0.5%	Reported strong preliminary Attruby revenue, pipeline progress, and 2026 milestones.
Jan 05	Conference participation	Neutral	-6.2%	Announced CEO presentation at J.P. Morgan Healthcare Conference with webcast access.
Jan 02	Investor webinar	Neutral	+2.3%	Scheduled achondroplasia webinar reviewing PROPEL 3 study and upcoming topline data.

Pattern Detected

Recent news, including debt management and business updates, has mostly aligned with modest share reactions, with one notable divergence on a broadly positive JPM update.

Recent Company History

Over the past month, BridgeBio has focused on capital structure and pipeline communication. On Jan 16, it priced $550M of 2033 convertible notes with concurrent share repurchases. Earlier, on Jan 14, it announced the proposed notes offering. At JPM on Jan 12, it highlighted strong preliminary 2025 Attruby revenue and multiple upcoming NDAs and readouts. Earlier January events centered on investor outreach and achondroplasia program visibility. Today’s inducement grants fit into ongoing equity-based compensation activity.

Market Pulse Summary

This announcement details routine equity compensation: 34,199 restricted stock units granted to 12 n...

Analysis

This announcement details routine equity compensation: 34,199 restricted stock units granted to 12 new employees under BridgeBio’s 2019 Inducement Equity Plan, structured to vest over time and encourage retention. Viewed against recent activity in convertible note offerings and strong preliminary 2025 revenue, it underscores ongoing reliance on equity incentives. Investors may watch future grants, overall share-based compensation levels, and upcoming clinical and regulatory milestones for additional context.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement equity plan

3 terms

restricted stock units financial

"approved equity grants to 12 new employees in restricted stock units for an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement equity plan financial

"under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”)"

An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com 

FAQ

What did BridgeBio (BBIO) announce on January 27, 2026 about employee equity?

BridgeBio announced inducement grants approved January 23, 2026 of 34,199 restricted stock units to 12 new employees under its inducement equity plan.

How do the BridgeBio (BBIO) inducement RSUs vest?

One‑quarter of each employee's RSUs vest on November 16, 2026, then one‑twelfth of the remaining shares vest quarterly thereafter, subject to continued employment.

Under which plan were BBIO inducement awards granted and when was it amended?

Awards were granted under the Amended and Restated 2019 Inducement Equity Plan, amended and restated on February 10, 2023 and December 13, 2023.

Why were the equity awards to new hires classified as inducements for BBIO?

The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees and how many total RSUs did BridgeBio grant in January 2026?

BridgeBio granted RSUs to 12 new employees for an aggregate of 34,199 shares.